Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer

PURPOSE: Men with metastatic castration-resistant prostate cancer (mCRPC) frequently develop resistance to androgen receptor signaling inhibitor (ARSI) treatment; therefore, new therapies are needed. Trophoblastic cell-surface antigen (TROP-2) is a transmembrane protein identified in prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Sperger, Jamie M., Helzer, Kyle T., Stahlfeld, Charlotte N., Jiang, Dawei, Singh, Anupama, Kaufmann, Katherine R., Niles, David J., Heninger, Erika, Rydzewski, Nicholas R., Wang, Liguo, Wang, Liewei, Yang, Rendong, Ren, Yanan, Engle, Jonathan W., Huang, Peng, Kyriakopoulos, Christos E., Slovin, Susan F., Soule, Howard R., Zhao, Shuang G., Kohli, Manish, Tagawa, Scott T., Cai, Weibo, Dehm, Scott M., Lang, Joshua M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Translational Cancer Mechanisms and Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261916/
https://www.ncbi.nlm.nih.gov/pubmed/36939530
http://dx.doi.org/10.1158/1078-0432.CCR-22-1305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10261916/
https://www.ncbi.nlm.nih.gov/pubmed/36939530
http://dx.doi.org/10.1158/1078-0432.CCR-22-1305

Ejemplares similares